Pay in 4 interest-free payments of $7.46 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
Commercially insured patients show a similar trend: 36% who began GLP-1 therapy in 2024 did not add another drug within a year, a significant rise from 13% in 2020
Injectable GLP-1s such as Wegovy have also demonstrated cardiovascular risk reduction in high-risk patients, an advantage not yet confirmed for the upcoming oral versions
Purdue reported Cornell-linked research showing households with at least one GLP-1 user changed how they buy food, with less overall grocery spending and relatively stronger purchase signals for foods like yogurt and fresh produce than for heavier, less nutrient-dense items
Research suggests the concern is legitimate
US$ 22.01
US$ 24.95
US$ 26.83
US$ 25.96
